Zacks Investment Research upgraded shares of Kura Oncology (NASDAQ:KURA) from a sell rating to a buy rating in a report released on Saturday, Zacks.com reports. The firm currently has $17.00 price target on the stock.
According to Zacks, “Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. “
A number of other analysts have also commented on KURA. Wedbush reaffirmed a positive rating on shares of Kura Oncology in a research note on Wednesday, September 4th. Deutsche Bank began coverage on Kura Oncology in a research note on Thursday, July 18th. They issued a buy rating and a $28.00 price target for the company. ValuEngine lowered Kura Oncology from a buy rating to a hold rating in a research note on Monday, October 21st. Cowen reaffirmed a buy rating on shares of Kura Oncology in a research note on Wednesday. Finally, BidaskClub raised Kura Oncology from a strong sell rating to a sell rating in a research report on Friday, October 18th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have issued a buy rating to the stock. The company has an average rating of Buy and a consensus target price of $26.11.
Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.03. On average, research analysts predict that Kura Oncology will post -1.61 EPS for the current fiscal year.
A number of institutional investors have recently made changes to their positions in KURA. Marshall Wace LLP purchased a new position in Kura Oncology during the first quarter valued at $372,000. SG Americas Securities LLC purchased a new position in Kura Oncology during the second quarter valued at $137,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Kura Oncology by 599.0% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,824 shares of the company’s stock valued at $56,000 after buying an additional 2,420 shares during the period. DekaBank Deutsche Girozentrale lifted its position in Kura Oncology by 63.3% during the second quarter. DekaBank Deutsche Girozentrale now owns 19,600 shares of the company’s stock valued at $388,000 after buying an additional 7,600 shares during the period. Finally, Swiss National Bank lifted its position in Kura Oncology by 36.1% during the second quarter. Swiss National Bank now owns 61,400 shares of the company’s stock valued at $1,209,000 after buying an additional 16,300 shares during the period. 84.97% of the stock is owned by institutional investors and hedge funds.
About Kura Oncology
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.